NASDAQ:BIS - ProShares UltraShort Nasdaq Biotech Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$20.45 -0.11 (-0.54 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$20.56
Today's Range$20.37 - $20.53
52-Week Range$17.52 - $29.66
Volume25,037 shs
Average Volume74,216 shs
Market Capitalization$31.22 million
P/E RatioN/A
Dividend Yield0.00%
Beta-2.81

About ProShares UltraShort Nasdaq Biotech (NASDAQ:BIS)

ProShares Ultra Nasdaq Biotechnology (the Fund) seeks investment results for a single day only, not for longer periods. The Fund seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day's returns compounded over the period, which will very likely differ from twice (200%) the return of the Nasdaq Biotechnology Index (the Index) for that period. The Fund does not seek to achieve its stated investment objective over a period of time greater than one day. The Fund invests in equity securities and derivatives that have similar daily performance characteristics as twice (200%) the daily return of the Index. The Fund invests in financial instruments whose value is derived from the value of an underlying asset, interest rate or index. ProShare Advisors LLC is the investment advisor of the Fund.

Receive BIS News and Ratings via Email

Sign-up to receive the latest news and ratings for BIS and its competitors with MarketBeat's FREE daily newsletter.

Basic Details

Issuer ProShares
Fund NameProShares UltraShort Nasdaq Biotechnology
Tax ClassificationRegulated Investment Company
SymbolNASDAQ:BIS
Inception Date4/7/2010
Fund ManagerMichael Neches, Devin Sullivan
Phone+1-240-4976400

Fund Focus

Asset ClassEquity
BenchmarkNASDAQ Biotechnology TR USD
CategorySector
FocusHealth Care
Development LevelDeveloped Markets
RegionNorth America

Fund Statistics

Assets Under Management$35.12 million
Average Daily Volume$109,729.00
Discount/Premium2.73%

ETF Expenses

Management Fee0.75%
Other Expenses0.36%
Total Expenses1.11%
Fee Waiver-0.16%
Net Expenses0.95%

Administrator, Advisor and Custodian

AdministratorJ.P. Morgan Investor Services Co.
AdvisorProShare Advisors LLC
CustodianJPMorgan Chase Bank, N.A.
DistributorSEI Investments Distribution Co.
Transfer AgentJPMorgan Chase Bank, N.A.
Trustee
Lead Market MakerVirtu Financial

Geographic Exposure of ProShares UltraShort Nasdaq Biotech (NASDAQ:BIS)
Currency Exposure of ProShares UltraShort Nasdaq Biotech (NASDAQ:BIS)
Sector Exposure of ProShares UltraShort Nasdaq Biotech (NASDAQ:BIS)
Industry Exposure of ProShares UltraShort Nasdaq Biotech (NASDAQ:BIS)

ProShares UltraShort Nasdaq Biotech (NASDAQ:BIS) Frequently Asked Questions

What is ProShares UltraShort Nasdaq Biotech's stock symbol?

ProShares UltraShort Nasdaq Biotech trades on the NASDAQ under the ticker symbol "BIS."

What price target have analysts set for BIS?

1 brokerages have issued 1 year price objectives for ProShares UltraShort Nasdaq Biotech's stock. Their predictions range from $0.16 to $0.16. On average, they expect ProShares UltraShort Nasdaq Biotech's stock price to reach $0.16 in the next twelve months. View Analyst Ratings for ProShares UltraShort Nasdaq Biotech.

Has ProShares UltraShort Nasdaq Biotech been receiving favorable news coverage?

News articles about BIS stock have trended somewhat positive recently, according to Accern. The research firm identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. ProShares UltraShort Nasdaq Biotech earned a media sentiment score of 0.02 on Accern's scale. They also assigned media headlines about the company an impact score of 47.43 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

Who are ProShares UltraShort Nasdaq Biotech's major shareholders?

ProShares UltraShort Nasdaq Biotech's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Jane Street Group LLC (0.70%). View Institutional Ownership Trends for ProShares UltraShort Nasdaq Biotech.

Which major investors are buying ProShares UltraShort Nasdaq Biotech stock?

BIS stock was purchased by a variety of institutional investors in the last quarter, including Jane Street Group LLC. View Insider Buying and Selling for ProShares UltraShort Nasdaq Biotech.

How do I buy shares of ProShares UltraShort Nasdaq Biotech?

Shares of BIS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ProShares UltraShort Nasdaq Biotech's stock price today?

One share of BIS stock can currently be purchased for approximately $20.45.

How big of a company is ProShares UltraShort Nasdaq Biotech?

ProShares UltraShort Nasdaq Biotech has a market capitalization of $31.22 million.

How can I contact ProShares UltraShort Nasdaq Biotech?

ProShares UltraShort Nasdaq Biotech's mailing address is SUITE 1000, 7501 WISCONSIN AVENUE, Bethesda, MD 20814, United States. The company can be reached via phone at +1-240-4976400.


MarketBeat Community Rating for ProShares UltraShort Nasdaq Biotech (BIS)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  40 (Vote Outperform)
Underperform Votes:  45 (Vote Underperform)
Total Votes:  85
MarketBeat's community ratings are surveys of what our community members think about ProShares UltraShort Nasdaq Biotech and other stocks. Vote "Outperform" if you believe BIS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

ProShares UltraShort Nasdaq Biotech (NASDAQ:BIS) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
1 Wall Street analysts have issued ratings and price targets for ProShares UltraShort Nasdaq Biotech in the last 12 months. Their average twelve-month price target is $0.16, suggesting that the stock has a possible downside of 99.22%. The high price target for BIS is $0.16 and the low price target for BIS is $0.16. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $0.16$0.16$0.16$0.16
Price Target Upside: 99.22% downsideN/AN/AN/A

ProShares UltraShort Nasdaq Biotech (NASDAQ:BIS) Consensus Price Target History

Price Target History for ProShares UltraShort Nasdaq Biotech (NASDAQ:BIS)
Show:

Earnings

Dividends

ProShares UltraShort Nasdaq Biotech (NASDAQ:BIS) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Headlines

ProShares UltraShort Nasdaq Biotech (NASDAQ BIS) News Headlines

Source:

SEC Filings

ProShares UltraShort Nasdaq Biotech (NASDAQ:BIS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

ProShares UltraShort Nasdaq Biotech (NASDAQ BIS) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.